Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
NCT ID NCT07538635
First seen Apr 25, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The goal is to see if this combination can better control the cancer and improve survival. The trial is currently recruiting 20 adults with high-risk large B-cell lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhengjiang, 310022, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Axicabtagene ciloleucel (a CAR-T cell therapy) combined with a stem cell transplant
What this could lead to
If successful, this combination could offer a more effective way to control aggressive lymphoma that has come back or not responded to standard treatments.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment involves intense chemotherapy and carries risks like severe side effects or the cancer not responding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.